Vimpat Demonstrated Greater Reduction in Seizure Frequency

• * Per 28 days from baseline to maintenance.
• †P=0.0023. Statistically significant difference as compared to placebo.

• Vimpat demonstrated onset of action as early as week 1¹
• In the intent-to-treat analysis of pooled data for the 3 pivotal studies, median percent reduction of seizure frequency was¹:

• 18% with current therapy + placebo (n=359)
• 33% with current therapy + Vimpat 200 mg/day (n=267)
• 37% with current therapy + Vimpat 400 mg/day (n=466)

See full study description and primary end point data from the Chung and Halasz trials.

Seizure reduction results with Vimpat were demonstrated in a challenging patient population. The baseline seizure status and treatment history of the study patients indicated that:

• 84% of patients were still experiencing seizures on 2 or more concomitant antiepileptic drugs (AEDs)
• Patients experienced an average of 10 to 17 seizures per month at baseline, despite treatment with 1, 2, or 3 AEDs
• 45% had tried 7 or more AEDs over their lifetime¹
• Approximately 17% of patients were being treated with vagus nerve stimulation (VNS)¹

In 49% of Patients, Vimpat Reduced Seizures by Half or More

• ‡ Per 28 days from baseline to maintenance.
• § P<0.05.

• For the intent-to-treat population of the 3 pivotal studies, ≥50% responders for patients treated with Vimpat 200 mg/day were 33% and 35%; with Vimpat 400 mg/day, 41%, 38%, and 41%; vs 22%, 18%, and 26% for those receiving placebo^2-4

Vimpat: More days without seizures

• Seizure-free days increased 8% with Vimpat 200 mg/day and 12% with Vimpat 400 mg/day vs 6% with placebo¹

Vimpat: More patients seizure free

• More patients taking Vimpat achieved seizure freedom during the maintenance phase than patients receiving placebo (3.3% vs 0.9%)^{1 ∥}

∥ 400 mg/day.

See full study description.

See Safety & Tolerability.